{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:58:24Z","timestamp":1772801904775,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2001,9]]},"DOI":"10.1067\/mhj.2001.117510","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"489-497","source":"Crossref","is-referenced-by-count":81,"title":["Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia"],"prefix":"10.1067","volume":"142","author":[{"given":"Carlos A.","family":"Dujovne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Zavoral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everton","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl M.","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2001.117510_bib1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","article-title":"Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study","volume":"67","author":"Hubert","year":"1983","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.117510_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00041433-199608000-00005","article-title":"Obesity and coronary heart disease","volume":"7","author":"Garrison","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"10.1067\/mhj.2001.117510_bib3","doi-asserted-by":"crossref","first-page":"419S","DOI":"10.1093\/ajcn\/63.3.419","article-title":"Effect of weight on cardiovascular disease","volume":"63","author":"Kannel","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"10.1067\/mhj.2001.117510_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.1993.00410090045006","article-title":"Excess body weight: an under-recognized contributor to high blood cholesterol levels in white American men","volume":"153","author":"Denke","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1067\/mhj.2001.117510_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archinte.1994.00420040061010","article-title":"Excess body weight: an under-recognized contributor to dyslipidemia in white American women","volume":"154","author":"Denke","year":"1994","journal-title":"Arch Intern Med"},{"issue":"B Suppl","key":"10.1067\/mhj.2001.117510_bib6","first-page":"14B","article-title":"Plasma triglyceride as a risk factor for cardiovascular disease","volume":"14","author":"Austin","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.1067\/mhj.2001.117510_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2001.117510_bib8","first-page":"841","article-title":"Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol","volume":"14","author":"Lamarche","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.1067\/mhj.2001.117510_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/clinchem\/37.7.1191","article-title":"Effect of weight loss on serum lipoprotein(a) concentrations in an obese population","volume":"37","author":"Corsetti","year":"1991","journal-title":"Clin Chem"},{"key":"10.1067\/mhj.2001.117510_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1067\/mhj.2001.117510_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajcn\/62.2.350","article-title":"Relation of weight loss to changes in serum lipids and lipoproteins in obese women","volume":"62","author":"Andersen","year":"1995","journal-title":"Am J Clin Nutr"},{"key":"10.1067\/mhj.2001.117510_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0149-2918(96)80057-9","article-title":"A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity","volume":"18","author":"Pi-Sunyer","year":"1996","journal-title":"Clin Ther"},{"key":"10.1067\/mhj.2001.117510_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0149-2918(96)80021-X","article-title":"Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia","volume":"18","author":"Dujovne","year":"1996","journal-title":"Clin Ther"},{"key":"10.1067\/mhj.2001.117510_bib14","first-page":"130","article-title":"Cholesterol reduction","author":"Goldman","year":"1996"},{"key":"10.1067\/mhj.2001.117510_bib15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2105\/AJPH.82.9.1251","article-title":"Weight loss attempts in adults: goals, duration, and rate of weight loss","volume":"82","author":"Williamson","year":"1992","journal-title":"Am J Public Health"},{"key":"10.1067\/mhj.2001.117510_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9343(97)89464-8","article-title":"Current views on obesity","volume":"100","author":"Stunkard","year":"1996","journal-title":"Am J Med"},{"key":"10.1067\/mhj.2001.117510_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1992.76","article-title":"Long-term weight control study: conclusions","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1067\/mhj.2001.117510_bib18","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long-term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity","year":"1996","journal-title":"JAMA"},{"issue":"1 Suppl","key":"10.1067\/mhj.2001.117510_bib19","first-page":"S22","article-title":"Pharmacological approaches to intervention","volume":"21","author":"Guy-Grand","year":"1997","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.1067\/mhj.2001.117510_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016","article-title":"Use and abuse of appetite-suppressant drugs in the treatment of obesity","volume":"119","author":"Bray","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1067\/mhj.2001.117510_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02244604","article-title":"Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl","volume":"100","author":"Luscombe","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1067\/mhj.2001.117510_bib22","first-page":"581","article-title":"In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor","volume":"283","author":"Gundlah","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1067\/mhj.2001.117510_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.bjp.0701311","article-title":"Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat","volume":"121","author":"Jackson","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1067\/mhj.2001.117510_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","article-title":"Sibutramine reduces food intake in non-dieting women with obesity","volume":"6","author":"Rolls","year":"1998","journal-title":"Obes Res"},{"key":"10.1067\/mhj.2001.117510_bib25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomized trial","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1067\/mhj.2001.117510_bib26","doi-asserted-by":"crossref","first-page":"553S","DOI":"10.1002\/j.1550-8528.1995.tb00227.x","article-title":"Sibutramine: a novel new agent for obesity treatment","volume":"3","author":"Ryan","year":"1995","journal-title":"Obes Res"},{"key":"10.1067\/mhj.2001.117510_bib27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1 Suppl","key":"10.1067\/mhj.2001.117510_bib28","first-page":"S30","article-title":"Sibutramine\u2014a review of clinical efficacy","volume":"21","author":"Lean","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1067\/mhj.2001.117510_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.ijo.0800540","article-title":"Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study","volume":"22","author":"Hanotin","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1067\/mhj.2001.117510_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1067\/mhj.2001.117510_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obesity Res"},{"key":"10.1067\/mhj.2001.117510_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1067\/mhj.2001.117510_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/j.1550-8528.1995.tb00120.x","article-title":"Assessing impact of weight on quality of life","volume":"3","author":"Kolotkin","year":"1995","journal-title":"Obes Res"},{"key":"10.1067\/mhj.2001.117510_bib34","series-title":"SF-36 health survey manual and interpretation guide","author":"Ware","year":"1993"},{"key":"10.1067\/mhj.2001.117510_bib35","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1 Suppl","key":"10.1067\/mhj.2001.117510_bib36","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1002\/j.1550-8528.1998.tb00685.x","article-title":"The case for medical management of obesity: a call for increased physician involvement","volume":"6","author":"Rippe","year":"1998","journal-title":"Obes Res"},{"issue":"1 Suppl","key":"10.1067\/mhj.2001.117510_bib37","first-page":"S2","article-title":"Defining success in obesity management","volume":"21","author":"Rossner","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1067\/mhj.2001.117510_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0895-4356(91)90265-B","article-title":"Regional obesity and risk of cardiovascular disease: the Framingham Study","volume":"44","author":"Kannel","year":"1991","journal-title":"J Clin Epidemiol"},{"key":"10.1067\/mhj.2001.117510_bib39","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.280.21.1843","article-title":"Abdominal adiposity and coronary heart disease in women","volume":"280","author":"Rexrode","year":"1998","journal-title":"JAMA"},{"key":"10.1067\/mhj.2001.117510_bib40","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(98)00186-7","article-title":"Current thinking in lipid lowering","volume":"104","author":"Ballantyne","year":"1998","journal-title":"Am J Med"},{"key":"10.1067\/mhj.2001.117510_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.1988.03410050061031","article-title":"Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study","volume":"260","author":"Manninen","year":"1988","journal-title":"JAMA"},{"key":"10.1067\/mhj.2001.117510_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/07853899109148041","article-title":"The Helsinki Heart Study: central findings and clinical implications","volume":"23","author":"Huttunen","year":"1991","journal-title":"Ann Med"},{"key":"10.1067\/mhj.2001.117510_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2001.117510_bib44","first-page":"9","article-title":"Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias","volume":"43","author":"Bays","year":"1994","journal-title":"Prog Drug Res"},{"key":"10.1067\/mhj.2001.117510_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"issue":"II Suppl","key":"10.1067\/mhj.2001.117510_bib46","first-page":"II44","article-title":"Pharmacologic management of triglycerides","volume":"22","author":"Hunninghake","year":"1999","journal-title":"Clin Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301253186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870301253186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:54:08Z","timestamp":1620003248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870301253186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["S0002870301253186"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2001.117510","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}